文献速递生殖医学

改良自然周期、程序化周期与促性腺激素刺激冻融胚胎移植周期早期妊娠的雌二醇与孕酮水平:一项随机对照试验

Estradiol and progesterone levels in early pregnancy after modified natural, programmed, and gonadotrophin-stimulated frozen embryo transfer cycles: a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2025-01-01

该平行开放标签随机对照药物试验于2021年4月至2024年12月在丹麦Herlev大学医院生殖门诊开展,纳入305个周期。排卵女性随机接受程序化周期(PC)或改良自然周期(mNC)冻融胚胎移植,无排卵女性随机接受PC或促性腺激素刺激周期(gSC)。主要发现移植日PC组雌二醇和孕酮水平高于mNC组,PC组与gSC组趋势相似但孕酮无显著差异。

要点

  • 排卵女性移植日PC组雌二醇0.86 nmol/l vs mNC组0.54 nmol/l,校正P<0.001。
  • 排卵女性移植日PC组孕酮68.5 nmol/l vs mNC组40.3 nmol/l,校正P<0.001。
  • PC组子代出生体重较mNC组估计治疗差292克(P<0.01)。

核心结论

  • 移植日PC组雌二醇和孕酮水平高于mNC组和gSC组,但这些发现的临床意义目前尚不明确,需进一步研究验证并探究对妊娠和胎儿发育的可能影响。

研究设计与样本

  • 平行开放标签随机对照药物试验,2021年4月至2024年12月在丹麦Herlev大学医院生殖门诊开展。
  • 目标样本量为每治疗组100个周期,把握度80%,共纳入305个周期,符合方案分析纳入257个周期。
  • 排卵女性随机接受PC或mNC,无排卵女性随机接受PC或gSC;自周期开始至孕龄9+6周共7个连续时间点采血。

主要发现

  • 排卵女性移植日雌二醇PC组0.86 nmol/l vs mNC组0.54 nmol/l(校正P<0.001),孕酮PC组68.5 nmol/l vs mNC组40.3 nmol/l(校正P<0.001)。
  • 排卵女性孕龄8+0周孕酮PC组87.5 nmol/l vs mNC组61.2 nmol/l(校正P=0.02)。
  • 无排卵女性移植日雌二醇PC组0.96 nmol/l vs gSC组0.54 nmol/l(校正P<0.01),孕酮无显著差异。
  • 妊娠率、活产率、流产率及周期取消率组间无差异。
  • 排卵女性PC组子代出生体重较mNC组估计治疗差292克(P<0.01),产后出血风险PC组22/40(55%)vs mNC组10/40(25%)(P=0.01)。

局限性

  • 无排卵两组均未达到每治疗组100个周期的目标样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are serum estradiol and progesterone levels higher in women treated with programmed cycle (PC) FET compared to women treated with a gonadotrophin-stimulated (gSC) FET or a modified natural cycle (mNC) FET during early pregnancy? SUMMARY ANSWER: Estradiol and progesterone levels are higher on the day of embryo transfer in women treated with PC compared to those treated with a mNC or gSC. WHAT IS KNOWN ALREADY: Various FET treatment regimens may affect the maternal hormone balance very differently in early pregnancy. Recent studies show that a PC is associated with increased risk of hypertensive pregnancy disorders, high birth weight, and postpartum hemorrhages. The underlying mechanism is not known but differences in hormone levels could play a role. STUDY DESIGN, SIZE, DURATION: This was a parallel open-label randomized controlled drug trial conducted from April 2021 until December 2024. The target sample size was 100 cycles in each treatment arm for a power of 80%. A total of 305 cycles were included and 257 were included in the per-protocol analysis. Ovulatory women were randomized to either a PC or a mNC. Anovulatory women were randomized to a PC or a gSC. Blood samples were obtained at seven consecutive time points from the start of the cycle until gestational age (GA) 9 + 6 weeks. Obstetric and neonatal follow-up was completed through the patients' digital medical records. Primary outcomes were differences in serum estradiol and progesterone between patient groups and treatment regimens. Secondary outcomes were to compare the type of cycle with reproductive, obstetric, and neonatal outcomes between groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: The trial was conducted in the Fertility Clinic at Herlev University Hospital, Denmark. Participants were women aged 18-40 years with BMI ≤35 kg/m2. Only women using autologous frozen blastocysts were eligible and all women had a normal wet cervical wet smear within the last 3 years. MAIN RESULTS AND THE ROLE OF CHANCE: For ovulatory women, estradiol and progesterone levels were higher in PCs on the day of embryo transfer day compared to mNCs (estradiol: 0.86 nmol/l vs 0.54 nmol/l, adjusted P < 0.001, progesterone: 68.5 nmol/l vs 40.3 nmol/l, adjusted P < 0.001), and progesterone levels were also higher in PCs at GA 8 + 0 (87.5 nmol/l vs 61.2 nmol/l, adjusted P = 0.02). For anovulatory women, the same trend was observed when comparing PCs to gSCs. Serum estradiol was significantly higher on the day of embryo transfer day (0.96 nmol/l vs 0.54 nmol/l, adjusted P < 0.01), though no significant differences in progesterone were found. We found no differences in pregnancy rates, live birth rates, pregnancy loss rates, or cancelation rates. Ovulatory women treated with PCs had significantly larger children with an estimated treatment difference of 292 grams (P < 0.01) compared to those treated with mNCs. Furthermore, we observed a higher risk of postpartum hemorrhages in PCs compared to mNCs (22/40 (55%) vs 10/40 (25%), P = 0.01). LIMITATIONS, REASONS FOR CAUTION: The target sample size of 100 cycles was not achieved in either of the anovulatory arms. WIDER IMPLICATIONS OF THE FINDINGS: This is the first randomized trial to investigate differences in maternal sex hormones between FET regimens. Although higher levels of estradiol and progesterone were demonstrated in PCs compared to mNCs and gSCs on the day of embryo transfer day, the significance of these findings is currently unclear. Further research is needed to verify these results and to examine possible effects on pregnancy and fetal development. STUDY FUNDING/COMPETING INTEREST(S): The study has received grants from Gedeon Richter Nordics AB (DK-2019-04, DK-2022-03, DK-2023-08, DK-2023-06, DK-2024-08) and a grant from the Gangsted-Rasmussen Foundation (ref. A39784). The study has also received a grant from the local research board at Herlev University Hospital. The funders of the trial had no role in the design and planning phase, data analysis, or interpretation of the results. Ongoing analyses of biobank samples have been funded by Merck A/S. M.S.S., H.U., and M.L.B. have no conflicts of interest. N.F.M. has, outside this work, received funding for congress registration from Gedeon Richter Nordics AB. P.F.S. has, outside this work, received grants from Merck A/S, Gedeon Richter Nordics AB, and Ferring Pharmaceuticals A/S. Outside this work, B.N. has received grants from Merck A/S, Gedeon Richter Nordics AB, and Ferring Pharmaceuticals A/S, personal fees from Ferring Pharmaceuticals A/S, travel support from Gedeon Richter Nordics AB, and participated in a data safety monitoring or advisory board for Ferring Pharmaceuticals A/S. TRIAL REGISTRATION NUMBER: 2020-001218-39 in EudraCT. TRIAL REGISTRATION DATE: 17 November 2020. DATE OF FIRST PATIENT’S ENROLMENT: 20 April 2021.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Mørch NF, Udengaard H, Borch ML, et al. Estradiol and progesterone levels in early pregnancy after modified natural, programmed, and gonadotrophin-stimulated frozen embryo transfer cycles: a randomized controlled trial. Hum Reprod. 2025. PMID: 40389227. doi:10.1093/humrep/deaf083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。